Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. 2006

Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
Center for Clinical Science Research, Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

CD4+CD25+ regulatory T (Treg) cells control immunologic tolerance and antitumor immune responses. Therefore, in vivo modification of Treg function by immunosuppressant drugs has broad implications for transplantation biology, autoimmunity, and vaccination strategies. In vivo bioluminescence imaging demonstrated reduced early proliferation of donor-derived luciferase-labeled conventional T cells in animals treated with Treg cells after major histocompatibility complex mismatch bone marrow transplantation. Combining Treg cells with cyclosporine A (CSA), but not rapamycin (RAPA) or mycophenolate mofetil (MMF), suppressed Treg function assessed by increased T-cell proliferation, graft-versus-host disease (GVHD) severity, and reduced survival. Expansion of Treg and FoxP3 expression within this population was lowest in conjunction with CSA, suggesting that calcineurin-dependent interleukin 2 (IL-2) production is critically required for Treg cells in vivo. The functional defect of Treg cells after CSA exposure could be reversed by exogenous IL-2. Further, the Treg plus RAPA combination preserved graft-versus-tumor (GVT) effector function against leukemia cells. Our data indicate that RAPA and MMF rather than CSA preserve function of Treg cells in pathologic immune responses such as GVHD without weakening the GVT effect.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008817 Mice, Mutant Strains Mice bearing mutant genes which are phenotypically expressed in the animals. Mouse, Mutant Strain,Mutant Mouse Strain,Mutant Strain of Mouse,Mutant Strains of Mice,Mice Mutant Strain,Mice Mutant Strains,Mouse Mutant Strain,Mouse Mutant Strains,Mouse Strain, Mutant,Mouse Strains, Mutant,Mutant Mouse Strains,Mutant Strain Mouse,Mutant Strains Mice,Strain Mouse, Mutant,Strain, Mutant Mouse,Strains Mice, Mutant,Strains, Mutant Mouse
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013045 Species Specificity The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species. Species Specificities,Specificities, Species,Specificity, Species
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015704 CD4 Antigens 55-kDa antigens found on HELPER-INDUCER T-LYMPHOCYTES and on a variety of other immune cell types. They are members of the immunoglobulin supergene family and are implicated as associative recognition elements in MAJOR HISTOCOMPATIBILITY COMPLEX class II-restricted immune responses. On T-lymphocytes they define the helper/inducer subset. T4 antigens also serve as INTERLEUKIN-15 receptors and bind to the HIV receptors, binding directly to the HIV ENVELOPE PROTEIN GP120. Antigens, CD4,CD4 Molecule,CD4 Receptor,CD4 Receptors,Receptors, CD4,T4 Antigens, T-Cell,CD4 Antigen,Receptors, Surface CD4,Surface CD4 Receptor,Antigen, CD4,Antigens, T-Cell T4,CD4 Receptor, Surface,CD4 Receptors, Surface,Receptor, CD4,Surface CD4 Receptors,T-Cell T4 Antigens,T4 Antigens, T Cell
D015996 Survival Rate The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods. Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival

Related Publications

Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
September 2004, European journal of immunology,
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
December 2002, Journal of immunology (Baltimore, Md. : 1950),
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
September 2005, Journal of autoimmunity,
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
June 2012, Journal of virology,
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
January 2005, Journal of immunotherapy (Hagerstown, Md. : 1997),
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
July 1998, The Journal of experimental medicine,
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
December 2004, Annals of the New York Academy of Sciences,
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
May 2006, Expert review of clinical immunology,
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
January 2006, Journal of immunology (Baltimore, Md. : 1950),
Robert Zeiser, and Vu H Nguyen, and Andreas Beilhack, and Martin Buess, and Stephan Schulz, and Jeanette Baker, and Christopher H Contag, and Robert S Negrin
January 2014, PloS one,
Copied contents to your clipboard!